Brokerages forecast that Myomo, Inc. (NASDAQ:MYO) will post earnings per share of ($0.17) for the current quarter, according to Zacks. Two analysts have issued estimates for Myomo’s earnings, with estimates ranging from ($0.17) to ($0.16). Myomo reported earnings per share of ($0.22) during the same quarter last year, which suggests a positive year-over-year growth rate of 22.7%. The company is scheduled to issue its next earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Myomo will report full-year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.64). For the next year, analysts expect that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.67) to ($0.25). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Myomo.
Myomo (NASDAQ:MYO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $1.30 million.
Separately, Roth Capital lowered Myomo from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.
MYO stock remained flat at $$0.49 during midday trading on Tuesday. The company’s stock had a trading volume of 30,747 shares, compared to its average volume of 130,863. The company’s 50-day moving average is $0.57 and its 200-day moving average is $0.72. Myomo has a twelve month low of $0.43 and a twelve month high of $1.87.
Myomo Company Profile
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Further Reading: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.